Filing search / Kineta, Inc. / "Supply Chain"

8-K

EX-99.5

KANT Kineta, Inc.

22 Dec 22

Kineta Completes Reverse Merger with Yumanity Therapeutics

5:02pm

operations; manufacturing, supply chain, and inspections; and statistical considerations for clinical trials during the COVID-19 public health emergency … , and to perform quality control and testing. If either Kineta or any third-party in the supply chain for materials used in the production of Kineta’s product

8-K

EX-99.6

KANT Kineta, Inc.

22 Dec 22

Kineta Completes Reverse Merger with Yumanity Therapeutics

5:02pm

includes guidance addressing resuming normal drug and biologics manufacturing operations; manufacturing, supply chain and inspections; and statistical

424B3

xz4m2k 5y

10 Nov 22

Prospectus supplement

4:21pm

8-K

EX-10.1

0dkxz

4 Mar 22

Entry into a Material Definitive Agreement

4:15pm

8-K

EX-99.1

hcotjw dzryxcqbhcan

15 May 20

Proteostasis Therapeutics Reports First Quarter 2020 Financial Results

4:11pm